Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial

Lignende værker

• Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
  af: Jiang, Tao, et al.
  Udgivet: (2020)
• Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study
  af: Wang, Xia, et al.
  Udgivet: (2021)
• Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
  af: Nobuaki Kobayashi, et al.
  Udgivet: (2020-08-01)
• Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
  af: Kobayashi, Nobuaki, et al.
  Udgivet: (2020)
• First-line osimertinib for leptomeningeal metastasis from lung adenocarcinoma with EGFR mutation as the initial and solitary site of postoperative recurrence
  af: Ono, Yuki, et al.
  Udgivet: (2020)